Fulgent Genetics Inc
FLGT
ISIN null / Valor 33851033
Fulgent Genetics Inc
UMushroom community rating:
About company
Fulgent Genetics Inc, founded in 2011, is a leading genomic testing company in the United States, offering a wide range of genetic testing services including single gene tests, rare disease tests, whole genome sequencing, copy number variation analysis, mitochondrial sequencing, and quality sequencing services. With 7 CLIA-certified and CAP-accredited labs across the country, Fulgent maintains high standards in diagnostic testing. In addition to its testing services, the company is also involved in therapeutic development, focusing on developing drug candidates for various cancers using innovative nanoencapsulation and targeted therapy approaches. By combining its expertise in testing and drug development, Fulgent aims to become a fully integrated precision medicine company, with a focus on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (18.10.2025):
Fulgent Genetics Inc reported its fourth quarter and full year 2024 financial results, showcasing growth in core revenue and maintaining a robust cash position despite experiencing GAAP losses.
Total Revenue
In the fourth quarter of 2024, Fulgent Genetics Inc achieved total revenue of $76.2 million, while the full year total revenue reached $283.5 million.
Core Revenue Growth
Core revenue grew by 14% year-over-year in the fourth quarter to $76.0 million and by 7% year-over-year for the full year, totaling $281.2 million.
GAAP and Non-GAAP Results
For the fourth quarter, the company reported a GAAP loss of $5.9 million ($0.19 per share) and a non-GAAP income of $1.2 million ($0.04 per share). For the full year, GAAP loss stood at $42.7 million ($1.41 per share) while non-GAAP income was $15.0 million ($0.49 per share).
Strong Cash Position
As of the end of 2024, Fulgent Genetics Inc maintained $828.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
886 M
Market cap (USD)
263,136
Daily traded volume (Shares)
18.64 / 17.8
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Maryam Jaouad
William Crawford-Stainsby
EQUITIES OF THE SAME SECTOR
